Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02217501 · ClinicalTrials.gov registry record · Phase 3
Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 159
- Enrollment target
NCT02217501 is a Phase 3 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 159 participants.
The verdict
NCT02217501, a Phase 3 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether clopidogrel 75 mg daily on a background of aspirin 75-100 mg/d for clinically indicated duration or for an additional 12 months will lead to an increased rate of primary patency, limb salvage, non-fatal myocardial infarction (MI), ischemic stroke, and survival, in patients receiving endovascular treatment of PAD at end of study treatment.
Interventions
- DRUG Clopidogrel
- DRUG Acetylsalicylic acid (ASA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2015-11 |
| Est. Completion | 2020-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02217501
The ClinicalTrials.gov registry entry for NCT02217501 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Clopidogrel is the first listed.
NCT02217501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02217501 about?
NCT02217501 is a clinical study titled "Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities". The purpose of this study is to evaluate whether clopidogrel 75 mg daily on a background of aspirin 75-100 mg/d for clinically indicated duration or for an additional 12 months will lead to an increased rate of primary patency, limb salvage, non-fatal myocardial infarction (MI), ischemic stroke, and...
What is the current status of trial NCT02217501?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 159 participants. The study started on 2015-11. Estimated completion is 2020-01-30.
What interventions are being tested in trial NCT02217501?
The interventions under investigation include: Clopidogrel (DRUG), Acetylsalicylic acid (ASA) (DRUG).
Who is sponsoring clinical trial NCT02217501?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.